DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ:ABMD) announced today that the first patient has been enrolled in PROTECT IV, a large, prospective, multi-center randomized controlled trial (RCT) that ...
Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non–Small-Cell Lung Cancer Treated in the US Community Setting We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback